Project Alzheimer’s Value Europe (PAVE) have together with Quantify colleagues published a study with new global estimates on the number of persons across the Alzheimer’s continuum in Alzheimer’s & Dementia: The Journal of the Alzheimer’s Association. The study shows that commonly cited estimates around 50 million persons with dementia hugely underestimate the prevalence when considering also predementia stages of Alzheimer’s disease. The numbers with beta-amyloid biomarker positive AD dementia and prodromal AD were estimated at 32 and 69 million respectively, whereas those in the at-risk preclinical AD population (beta-amyloid biomarker positive but without overt symptoms) were estimated at 315 million. This corresponds to 22% of the global population above the age of 50 years, who may benefit from prevention strategies and future disease modifying treatments.
“We are thrilled about publishing this study, which gives new perspectives on the huge burden of AD, says Anders Gustavsson, first author and co-founder of Quantify. He continues, “PAVE is a very important initiative as it joins so many stakeholders from academia, industry and decision makers. I am grateful for Quantify to be given the opportunity to contribute to this effort and thank sponsors Roche and Biogen for their initiative and persistent engagement, and the clinical experts of the study steering group for their invaluable advice.”
You can find the full study here: https://lnkd.in/gJheyVpa